What do systematic reviews say?

Dexrazoxane vs no cardioprotective intervention or placebo

The review found no eligible studies for this question.

• Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found